Spectris solaris ep mr

MR Imaging was performed with a 1.5T scanner (Magnetom Symphony, Siemens Medical System, Erlangen, Germany) equipped with a phased-array body coil. Patients were placed in a supine, headfirst position. Mild rectal lumen distension was achieved with 60-90 ml of ultrasound gel or superparamagnetic contrast medium (Lumirem; Guerbet, Roissy CdG Cedex, France) introduced per rectum. Pre-contrast sagittal and axial T2 weight (W) 2D turbo spin-echo (TSE) images of the pelvis were obtained. Axial, dynamic, contrast enhanced T1W, FLASH 3D gradient-echo (GRE) images were acquired for the qualitative (q) MRI analysis (inspective analysis of TIC). We obtained one sequence before and ten sequences, without any delay, after IV injection of 2 ml/kg of a positive, gadolinium based paramagnetic contrast medium (Gd- DOTA, Dotarem, Guerbet, Roissy CdG Cedex, France). The contrast medium was injected using Spectris Solaris® EP MR (MEDRAD Inc., Indianola, PA), with a flow rate of 2 ml/s, followed by a 10-mL saline flush at the same rate. Total acquisition time for pre-contrast and ten post-contrast sequences was 6.4 minutes. Sagittal, axial and coronal post contrast T1W 2D TSE, with and without fat saturation were obtained. The details of pulse Sequence Parameters are reported in Table 5.

MR imaging was performed using a 1.5 T MR (Magnetom Symphony, with Total Imaging Matrix Package, Siemens, Erlangen, Germany) with an 8-element body and phased array coils. The MRI study protocol included conventional sequences that are T1 weighted (W), without contrast medium administration, and T2-W, which includes Diffusion-Weighted Imaging (DWI) with seven b values to obtain functional parameters with a mono-exponential model and T1-W sequences after the administration of the contrast medium. The MR protocol was described in detail in [25 (link),28 (link)].
According to the different phases of patient management, our study protocol includes the possibility to administrate a liver-specific contrast (in pre-surgical setting) and a non-liver-specific contrast (in the characterization and staging phase). In this study, we assessed images obtained with a non-specific agent: the Gd-BT-DO3A (Gadovist, Bayer Schering Pharma, Germany). All patients received 0.1 mL/kg of Gd-BT-DO3A by means of a power injector (Spectris Solaris^® EP MR, MEDRAD Inc., Indianola, IA, USA), at an infusion rate of 2 mL/s.
The contrast study protocol includes the arterial phase (35 s delay), portal/venous phase (90 s) and equilibrium phases (120 s).

A Magnetom Symphony 1.5 T scanner (Siemens, Erlangen, Germany) and a Magnetom Aera (Siemens) 1.5 T scanner equipped with an 8-element body and phased array coils were used to acquire an MRI study that includes sequences before and after intravenous (IV) contrast agent (CA) injection.
In this study, radiomic features extraction was made on volumetric interpolated breath-hold examination (VIBE) T1-weighted SPAIR with controlled respiration used to acquire images after IV CA injection with a liver-specific CA (0.1 mL/kg of Gd-EOB-BPTA, Primovist, Bayer Schering Pharma, Berlin, Germany) as descripted in [26 (link),27 (link)].
The VIBE T1-W sequence was acquired with two different flip angles (10 and 30 degrees). A power injector (Spectris Solaris^® EP MR, MEDRAD, Inc., Indianola, IA, USA) was used to administer the CA at an infusion rate of 2 mL/s. VIBE T1-w images were acquired in four different phases: arterial phase (35 s delay), portal venous phase (90 s), late/transitional phase (120 s), and hepatobiliary excretion phase (20 min). MRI protocol details are reported in Table 2.